Corcept Therapeutics Inc (CORT) Q2 2017 10-Q Quarterly Earnings

Short answer

Corcept Therapeutics Inc (CORT) filed its Q2 2017 10-Q quarterly report on Aug 2, 2017 for the quarter ended Jun 30, 2017.

AI summary of MD&A and risk factor updates

Quarterly net product revenue $35.6M vs $19.7M, up $15.9M YoY
GAAP net income $12.647M vs unavailable comparative figure, basic EPS $0.11 vs $0.01
Cost-of-sales margin 2.2% vs 2.2% YoY, R&D expenses $7.9M vs $5.7M
Best product Korlym, $35.6M quarterly net product revenue, oncology R&D $1.238M vs Cushing’s syndrome $1.933M
Cash, equivalents and securities $67.7M vs $51.5M, operating cash flow $25.1M, financing payments $10.5M
Outlook: higher R&D and SG&A spending, operations funded without additional financing expected

Regulatory risk: Trump administration executive orders, including “two-for-one” rules, could delay FDA oversight and threaten Korlym compliance
Reimbursement risk: PPACA uncertainty and CMS pricing-rule changes could reduce Korlym coverage, demand, or reimbursement
Operational risk: PCAS supplies all Korlym API, while Alcami produces all tablets, creating concentrated manufacturing dependence
Competitive risk: Novartis’ Signifor and osilodrostat programs could pressure Korlym adoption and revenue
Financial risk: Insufficient Korlym revenue may require additional capital, potentially diluting stockholders or delaying development programs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.